Edgewise Price Cash Flow Ratio vs Begin Period Cash Flow Analysis

EWTX Stock

USD 33.00 0.80 2.48%

Edgewise Therapeutics financial indicator trend analysis is much more than just examining Edgewise Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Edgewise Therapeutics is a good investment. Please check the relationship between Edgewise Therapeutics Price Cash Flow Ratio and its Begin Period Cash Flow accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edgewise Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.

Price Cash Flow Ratio vs Begin Period Cash Flow

Price Cash Flow Ratio vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Edgewise Therapeutics Price Cash Flow Ratio account and Begin Period Cash Flow. At this time, the significance of the direction appears to have strong relationship.

The correlation between Edgewise Therapeutics' Price Cash Flow Ratio and Begin Period Cash Flow is 0.63. Overlapping area represents the amount of variation of Price Cash Flow Ratio that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Edgewise Therapeutics, assuming nothing else is changed. The correlation between historical values of Edgewise Therapeutics' Price Cash Flow Ratio and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price Cash Flow Ratio of Edgewise Therapeutics are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Price Cash Flow Ratio i.e., Edgewise Therapeutics' Price Cash Flow Ratio and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.63

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Price Cash Flow Ratio

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Edgewise Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Edgewise Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edgewise Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.Selling General Administrative is likely to rise to about 24.6 M in 2024, despite the fact that Issuance Of Capital Stock is likely to grow to (527.2 K).

	2021	2022	2023	2024 (projected)
Interest Income	402K	4.0M	14.2M	14.9M
Net Interest Income	402K	4.0M	14.2M	14.9M

Interest Income Net Interest Income

Edgewise Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital	Property Plant Equipment	Non Currrent Assets Other	Other Assets	Deferred Long Term Liab
Total Assets		-0.38	0.99	0.99	0.97	0.94	0.81	-0.84	-0.86	0.98	0.82	0.93	1.0	0.74	-0.39	0.97	0.97	-0.2	0.97	0.77	1.0	1.0	0.83	0.55	-0.95	-0.97
Short Long Term Debt Total	-0.38		-0.41	-0.43	-0.58	-0.58	-0.47	0.55	0.46	-0.43	-0.27	-0.46	-0.37	-0.42	1.0	-0.54	-0.55	0.97	-0.58	-0.46	-0.37	-0.37	-0.48	-0.28	0.55	0.56
Other Current Liab	0.99	-0.41		1.0	0.97	0.95	0.86	-0.78	-0.91	0.95	0.74	0.95	0.98	0.82	-0.42	0.98	0.99	-0.23	0.97	0.82	0.99	0.99	0.87	0.46	-0.96	-0.97
Total Current Liabilities	0.99	-0.43	1.0		0.97	0.95	0.86	-0.8	-0.9	0.97	0.77	0.97	0.99	0.8	-0.44	0.99	0.99	-0.25	0.97	0.82	0.99	0.99	0.88	0.51	-0.96	-0.97
Total Stockholder Equity	0.97	-0.58	0.97	0.97		0.95	0.8	-0.89	-0.84	0.97	0.81	0.93	0.97	0.73	-0.59	0.99	0.99	-0.43	1.0	0.75	0.97	0.97	0.82	0.59	-0.95	-0.99
Net Tangible Assets	0.94	-0.58	0.95	0.95	0.95		0.91	-0.76	-0.95	0.92	0.66	0.9	0.94	0.84	-0.59	0.95	0.96	-0.38	0.95	0.89	0.94	0.94	0.92	0.38	-0.99	-0.96
Property Plant And Equipment Net	0.81	-0.47	0.86	0.86	0.8	0.91		-0.52	-0.98	0.79	0.42	0.89	0.8	0.93	-0.47	0.84	0.85	-0.25	0.8	0.99	0.81	0.8	1.0	0.14	-0.94	-0.79
Net Debt	-0.84	0.55	-0.78	-0.8	-0.89	-0.76	-0.52		0.54	-0.9	-0.95	-0.77	-0.84	-0.34	0.57	-0.87	-0.81	0.46	-0.89	-0.43	-0.84	-0.84	-0.55	-0.87	0.76	0.87
Retained Earnings	-0.86	0.46	-0.91	-0.9	-0.84	-0.95	-0.98	0.54		-0.81	-0.45	-0.87	-0.85	-0.95	0.46	-0.86	-0.89	0.24	-0.84	-0.98	-0.86	-0.86	-0.97	-0.12	0.96	0.85
Accounts Payable	0.98	-0.43	0.95	0.97	0.97	0.92	0.79	-0.9	-0.81		0.88	0.95	0.98	0.66	-0.44	0.98	0.95	-0.26	0.97	0.73	0.98	0.98	0.82	0.67	-0.93	-0.95
Cash	0.82	-0.27	0.74	0.77	0.81	0.66	0.42	-0.95	-0.45	0.88		0.72	0.83	0.24	-0.28	0.8	0.74	-0.18	0.81	0.32	0.82	0.83	0.46	0.91	-0.67	-0.79
Non Current Assets Total	0.93	-0.46	0.95	0.97	0.93	0.9	0.89	-0.77	-0.87	0.95	0.72		0.93	0.81	-0.47	0.97	0.96	-0.29	0.93	0.83	0.93	0.93	0.91	0.52	-0.94	-0.9
Cash And Short Term Investments	1.0	-0.37	0.98	0.99	0.97	0.94	0.8	-0.84	-0.85	0.98	0.83	0.93		0.72	-0.39	0.97	0.97	-0.19	0.97	0.76	1.0	1.0	0.82	0.56	-0.94	-0.97
Common Stock Shares Outstanding	0.74	-0.42	0.82	0.8	0.73	0.84	0.93	-0.34	-0.95	0.66	0.24	0.81	0.72		-0.43	0.76	0.81	-0.24	0.73	0.96	0.73	0.73	0.92	-0.07	-0.85	-0.73
Non Current Liabilities Total	-0.39	1.0	-0.42	-0.44	-0.59	-0.59	-0.47	0.57	0.46	-0.44	-0.28	-0.47	-0.39	-0.43		-0.55	-0.56	0.96	-0.59	-0.46	-0.39	-0.39	-0.48	-0.3	0.56	0.58
Other Current Assets	0.97	-0.54	0.98	0.99	0.99	0.95	0.84	-0.87	-0.86	0.98	0.8	0.97	0.97	0.76	-0.55		0.99	-0.37	0.99	0.79	0.97	0.97	0.86	0.59	-0.96	-0.97
Other Stockholder Equity	0.97	-0.55	0.99	0.99	0.99	0.96	0.85	-0.81	-0.89	0.95	0.74	0.96	0.97	0.81	-0.56	0.99		-0.39	0.99	0.81	0.97	0.97	0.86	0.49	-0.96	-0.98
Total Liab	-0.2	0.97	-0.23	-0.25	-0.43	-0.38	-0.25	0.46	0.24	-0.26	-0.18	-0.29	-0.19	-0.24	0.96	-0.37	-0.39		-0.43	-0.23	-0.19	-0.19	-0.25	-0.28	0.35	0.41
Net Invested Capital	0.97	-0.58	0.97	0.97	1.0	0.95	0.8	-0.89	-0.84	0.97	0.81	0.93	0.97	0.73	-0.59	0.99	0.99	-0.43		0.75	0.97	0.97	0.82	0.59	-0.95	-0.99
Property Plant And Equipment Gross	0.77	-0.46	0.82	0.82	0.75	0.89	0.99	-0.43	-0.98	0.73	0.32	0.83	0.76	0.96	-0.46	0.79	0.81	-0.23	0.75		0.77	0.76	0.98	0.02	-0.91	-0.75
Total Current Assets	1.0	-0.37	0.99	0.99	0.97	0.94	0.81	-0.84	-0.86	0.98	0.82	0.93	1.0	0.73	-0.39	0.97	0.97	-0.19	0.97	0.77		1.0	0.82	0.55	-0.94	-0.97
Net Working Capital	1.0	-0.37	0.99	0.99	0.97	0.94	0.8	-0.84	-0.86	0.98	0.83	0.93	1.0	0.73	-0.39	0.97	0.97	-0.19	0.97	0.76	1.0		0.82	0.56	-0.94	-0.97
Property Plant Equipment	0.83	-0.48	0.87	0.88	0.82	0.92	1.0	-0.55	-0.97	0.82	0.46	0.91	0.82	0.92	-0.48	0.86	0.86	-0.25	0.82	0.98	0.82	0.82		0.19	-0.94	-0.8
Non Currrent Assets Other	0.55	-0.28	0.46	0.51	0.59	0.38	0.14	-0.87	-0.12	0.67	0.91	0.52	0.56	-0.07	-0.3	0.59	0.49	-0.28	0.59	0.02	0.55	0.56	0.19		-0.4	-0.54
Other Assets	-0.95	0.55	-0.96	-0.96	-0.95	-0.99	-0.94	0.76	0.96	-0.93	-0.67	-0.94	-0.94	-0.85	0.56	-0.96	-0.96	0.35	-0.95	-0.91	-0.94	-0.94	-0.94	-0.4		0.95
Deferred Long Term Liab	-0.97	0.56	-0.97	-0.97	-0.99	-0.96	-0.79	0.87	0.85	-0.95	-0.79	-0.9	-0.97	-0.73	0.58	-0.97	-0.98	0.41	-0.99	-0.75	-0.97	-0.97	-0.8	-0.54	0.95

Click cells to compare fundamentals

Edgewise Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Edgewise Stock Analysis

When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Edgewise Price Cash Flow Ratio vs Begin Period Cash Flow Analysis

Price Cash Flow Ratio vs Begin Period Cash Flow

Price Cash Flow Ratio vs Begin Period Cash Flow Correlation Analysis

Correlation Coefficient

Price Cash Flow Ratio

Begin Period Cash Flow

Edgewise Therapeutics fundamental ratios Correlations

Edgewise Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Edgewise Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Total Current Liabilities	+ 1.0	Other Current Liab
Net Invested Capital	+ 1.0	Total Stockholder Equity

Deferred Long Term Liab	- 0.99	Net Invested Capital
Other Assets	- 0.99	Net Tangible Assets
Deferred Long Term Liab	- 0.99	Total Stockholder Equity
Deferred Long Term Liab	- 0.98	Other Stockholder Equity
Property Plant And Equipment Gross	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Property Plant And Equipment Net